NCT00697801View on ClinicalTrials.gov

Study of MAP0010 in Asthmatic Children and Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Asthma
Interventions
DRUG

MAP0010 low dose

a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks

DRUG

MAP0010 high dose

a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks

DRUG

Placebo

Placebo delivered by nebulization twice daily for 6 weeks

Trial Locations (1)

Unknown

San Diego

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT00697801 - Study of MAP0010 in Asthmatic Children and Adolescents | Biotech Hunter | Biotech Hunter